Healthcare Services

Global Predictive And Presymptomatic Testing Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

April 6, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Predictive And Presymptomatic Testing Market Over The 2026–2030 Period?

The predictive and presymptomatic testing market has experienced swift expansion in recent years. It is anticipated to grow from $5.78 billion in 2025 to $6.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. This historical growth is attributable to advancements in genetic sequencing technologies, increasing awareness of inherited disease risks, the expansion of clinical genetic testing services, the rise of oncology and neurology testing programs, and a reduction in the costs of genetic testing.

The predictive and presymptomatic testing market size is projected to experience substantial growth over the coming years. This sector is expected to expand to $9.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This anticipated growth can be attributed to several factors during the forecast period, including the increasing demand for personalized medicine, the rising integration of AI in genomic analysis, the expansion of population-scale screening programs, a growing focus on preventive healthcare strategies, and increasing regulatory support for genetic diagnostics. Prominent trends observed in the forecast period involve the growing adoption of preventive genetic screening, the rising use of risk-based disease prediction models, the expansion of genetic counseling services, an increased focus on early disease detection, and the integration of genomic data in clinical decision-making.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20594&type=smp

Which Economic Or Industry Drivers Are Impacting The Predictive And Presymptomatic Testing Market?

The increasing occurrence of genetic conditions is projected to fuel the expansion of the predictive and presymptomatic testing market in the future. These disorders are illnesses stemming from deoxyribonucleic acid (DNA) irregularities, encompassing gene mutations and chromosomal alterations, exemplified by conditions like cystic fibrosis and Down syndrome. The growing frequency of genetic disorders is linked to elements such as older maternal age, environmental influences, and improved diagnostic techniques. Predictive and presymptomatic testing is vital for lowering the incidence of genetic disorders by pinpointing at-risk individuals prior to symptom onset. This proactive strategy facilitates early interventions or modifications to lifestyle that can either prevent or lessen the severity of these conditions. For example, data from June 2023, provided by the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, indicated that gene therapies in Phase III clinical trials saw a 10% rise in quarter 3, 2023, marking the initial quarterly growth since quarter 3, 2022. Consequently, the increased occurrence of genetic conditions is propelling the predictive and presymptomatic testing market.

How Is The Predictive And Presymptomatic Testing Market Segmented Across Key Categories?

The predictive and presymptomatic testing market covered in this report is segmented –

1) By Test Type: Predictive Testing, Presymptomatic Testing

2) By Application: Cancer Genetic Testing, Cardiovascular Genetic Testing, Neurological Genetic Testing, Other Applications

3) By End User: Hospitals And Clinics, Diagnostic Laboratories

Subsegments:

1) By Predictive Testing: Genetic Testing for Inherited Conditions, Cancer Risk Prediction, Cardiovascular Disease Prediction, Neurodegenerative Disease Risk Prediction, Genetic Screening for Autosomal Dominant Disorders

2) By Presymptomatic Testing: Huntington’s Disease Testing, Hereditary Cancer Risk Testing, Cystic Fibrosis Presymptomatic Testing, Early-Onset Alzheimer’s Disease Testing, Presymptomatic Genetic Testing for Familial Diseases

How Are Trends Shaping The Direction Of The Predictive And Presymptomatic Testing Market?

Leading companies in the predictive and presymptomatic testing market are focused on developing advanced multi-gene testing solutions that feature enhanced genetic risk-scoring capabilities, aiming to enable earlier disease prediction and improve personalized prevention strategies. Polygenic-enabled panels integrate the sequencing of clinically relevant hereditary-risk genes with the analysis of multiple common variants, offering a more comprehensive and individualized assessment of future disease likelihood than traditional single-gene tests. For instance, in November 2025, Myriad Genetics Inc., a U.S.-based molecular diagnostics company, broadened its MyRisk Hereditary Cancer Test to encompass 63 clinically actionable genes across more than 11 cancer types. This expanded panel combines next-generation sequencing with personalized lifetime and five-year cancer-risk estimates, allowing physicians to guide proactive clinical decision-making. The product effectively enhances risk detection even in individuals without strong family histories and supports targeted surveillance, earlier screening initiation, and preventive care planning.

Who Are The Dominant Players Shaping The Predictive And Presymptomatic Testing Market Landscape?

Major companies operating in the predictive and presymptomatic testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Mayo Clinic, Quest Diagnostics Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Peter MacCallum Cancer Centre, Myriad Genetics Inc., SomaLogic Inc., Siteman Cancer Center, Dante Labs S.R.L., Mapmygenome, Manipal Health Enterprises, Gene Vision, Reliance Diagnostic, GenepoweRx, Personal Genomics, Apollo Hospitals Enterprise Limited, Cardio Diagnostics Inc.

Read the full predictive and presymptomatic testing market report here:

https://www.thebusinessresearchcompany.com/report/predictive-and-presymptomatic-testing-global-market-report

What Are The Top-Performing Regions Within The Predictive And Presymptomatic Testing Market?

North America was the largest region in the predictive and presymptomatic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive and presymptomatic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Predictive And Presymptomatic Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20594&type=smp

Browse Through More Reports Similar to the Global Predictive And Presymptomatic Testing Market 2026, By The Business Research Company

Central Precocious Puberty Global Market Report

https://www.thebusinessresearchcompany.com/report/central-precocious-puberty-global-market-report

Premature Ejaculation Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/premature-ejaculation-treatment-global-market-report

Hormone Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795